The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.

The first-of-a-kind brain-stimulation device approved to treat attention-deficit/hyperactivity disorder (ADHD) in the US has ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that the U.S. Food and Drug Administration (FDA) has accepted for priority ...

FDA fast tracks ADHD drug centanafadine, targeting approval by July 24 for treatment across all age groups, based on phase 3 trial results.

Otsuka Pharmaceutical announced that the FDA is reviewing investigational centanafadine -- a potential first-in-class ...

KANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...

KANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (CING) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...

The use of medication to treat Attention-Deficit Hyperactivity Disorder (ADHD) has risen sharply in the UK, largely due to ...

Treatment linked to reduced rates of first occurrence of suicidal behaviors, substance misuse, transport accidents, criminality. HealthDay News — Attention-deficit ...

Despite concerns about increased stimulant prescribing, nonmedical use of ADHD drugs among adolescents has declined in the last 20 years, a University of Michigan study shows. While medical use of ...

The use of medications for Attention-Deficit Hyperactivity Disorder (ADHD) has increased substantially across Europe over the past decade, with the ...